• Nirmatrelvir (PF-07321332): 3CLpro Research Guide

  2026-08-10

  Nirmatrelvir, also called PF-07321332, is an orally bioavailable SARS-CoV-2 3CLpro inhibitor that blocks viral polyprotein processing. Its defined molecular properties and protease-centered mechanism support controlled antiviral therapeutics research, while solubility and assay-boundary considerations remain important.

• Wnt agonist 1: Workflow for Wnt Signaling Studies

  2026-08-09

  Wnt agonist 1 (BML-284) provides a practical chemical handle for testing β-catenin–TCF signaling in differentiation, developmental, and cancer models. This workflow connects pathway activation with paired reporter, transcriptional, redox, and phenotype readouts while highlighting controls that prevent overinterpretation.

• Vancomycin hydrochloride for resistance assays

  2026-08-08

  Vancomycin hydrochloride provides a mechanism-defined positive control for Gram-positive bacteria inhibition, susceptibility testing, selective media, and resistance-window experiments. This guide connects practical bench workflows with the MIC–MPC framework reported in pneumonia research while clearly separating validated evidence from assay starting conditions.

• SD 169: Practical p38 MAPK Research Workflows

  2026-08-07

  SD 169 (indole-5-carboxamide) supports controlled studies of p38α/β signaling in inflammation, type 1 diabetes research, apoptosis, and nerve repair. This workflow-centered guide connects dose preparation, phospho-protein assays, dephosphorylation kinetics, and phenotype-level validation while highlighting practical troubleshooting limits.

• Calnexin-Dependent Rescue of CFTR Variants: Mechanistic Insi

  2026-08-07

  Tedman et al. employ deep mutational scanning to systematically profile how the ER chaperone calnexin impacts the expression and pharmacological rescue of over 200 clinical CFTR variants. Their findings reveal domain- and mutation-specific modulation of CFTR folding and corrector efficacy, providing a framework for personalized cystic fibrosis research and therapeutic development.

• Patient-Derived Gastric Cancer Assembloids Advance Drug Resp

  2026-08-06

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids and stromal cell subpopulations, offering a more physiologically relevant platform for investigating tumor–stroma interactions and drug resistance. The findings highlight significant differences in gene expression and therapeutic sensitivity compared to traditional organoid monocultures, supporting enhanced personalized drug screening.

• Epalrestat: Advancing Neuroprotection Beyond Diabetic Resear

  2026-08-06

  Explore how Epalrestat, a high-purity aldose reductase inhibitor from APExBIO, is redefining translational research strategies in neurodegeneration. This article integrates mechanistic insights—such as KEAP1/Nrf2 pathway activation in Parkinson’s disease models—with practical protocol parameters and strategic guidance, moving the discussion beyond standard product overviews.

• Strategic Leverage of 5-Aminolevulinic Acid HCl in Heme Path

  2026-08-05

  Explore how 5-Aminolevulinic acid HCl (5-ALA HCl) uniquely empowers translational researchers to dissect heme biosynthesis, model immune evasion, and advance antineoplastic strategies. Drawing from mechanistic insight and new findings on Salmonella-driven immune modulation, this thought-leadership piece offers actionable guidance and protocol clarity, while distinctly expanding the conversation beyond standard product narratives.

• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding

  2026-08-05

  Oliveira et al. (2025) reveal that naturally occurring angiotensin peptides, including several short fragments, significantly increase the binding affinity of the SARS-CoV-2 spike protein to the AXL receptor. This mechanistic insight bridges cardiovascular peptide research and COVID-19 pathogenesis, underscoring the importance of angiotensin signaling in infectious disease models.

• T-5224 and AP-1 Inhibition: Translational Leverage in Inflam

  2026-08-04

  This article explores the mechanistic, experimental, and translational landscape of T-5224, a selective C-Fos/AP-1 inhibitor, emphasizing its validated roles in inflammation, arthritis models, and recent advances in oncology. Integrating recent findings on ferroptosis induction in multiple myeloma, the discussion guides translational researchers toward strategic study design and highlights APExBIO's T-5224 as a uniquely positioned research tool for dissecting AP-1–mediated disease processes.

• Applied α-Bungarotoxin: Precision Nicotinic Receptor Blockad

  2026-08-04

  Harness α-Bungarotoxin for targeted nicotinic receptor blockade in advanced neurobiology and placental models. This article details experimental workflows, troubleshooting strategies, and new translational insights—empowering researchers to unravel cholinergic mechanisms with confidence.

• METTL14–lncRNA Axis Controls Inflammation in Ulcerative Coli

  2026-08-03

  A recent study reveals that METTL14-mediated m6A modification of the lncRNA DHRS4-AS1 regulates inflammatory responses in ulcerative colitis (UC) through the DHRS4-AS1/miR-206/A3AR signaling axis. These findings clarify a previously unrecognized epigenetic mechanism driving UC pathogenesis and identify new intervention points for preclinical inflammation research.

• Natural Compounds Target SARS-CoV-2 Main Protease and Spike

  2026-08-03

  This study deploys molecular docking and dynamics to identify several repurposed vitamins as potential inhibitors of SARS-CoV-2 main protease (3CLpro) and the receptor-binding domain (RBD) of the spike protein. The findings add to the toolkit for antiviral therapeutics research by highlighting new molecular scaffolds for COVID-19 intervention strategies.

• Endothelial SGK1 Drives Vascular Stiffening via Actin Regula

  2026-08-02

  Zhang et al. demonstrate that endothelial SGK1 mediates vascular stiffening in response to salt and mineralocorticoid exposure, providing direct mechanistic evidence that SGK1-induced actin polymerization is central to this process. Pharmacological inhibition of SGK1 with EMD638683 in human endothelial cells prevented salt- and aldosterone-induced cellular stiffening, highlighting translational targets for hypertension and cardiovascular risk.

• Ruxolitinib Triggers Caspase-Dependent Cell Death in ATC via

  2026-08-01

  The referenced study uncovers a novel mechanism by which ruxolitinib induces apoptosis and pyroptosis in anaplastic thyroid carcinoma (ATC) cells—via transcriptional suppression of DRP1 and disruption of mitochondrial fission. These findings highlight new therapeutic directions for aggressive thyroid cancers and inform the use of pan-caspase inhibitors in mechanistic research.

543 records 8/37 page Previous Next First page 上5页 678910 下5页 Last page